PIASy-mediated Sumoylation of SREBP1c Regulates Hepatic Lipid Metabolism Upon Fasting Signaling
Overview
Affiliations
SREBP1c is a key transcription factor that regulates de novo lipogenesis during anabolic periods. However, the molecular mechanisms involved in the suppression of SREBP1c under nutritional deprivation are largely unknown. In this study, we demonstrate that the small ubiquitin-related modifier (SUMO) E3 ligase, a protein inhibitor of activated STAT Y (PIASy), sumoylates SREBP1c at Lys98, leading to suppression of the hepatic lipogenic program upon fasting-induced signals. In primary hepatocytes, ablation of PIASy stimulated intracellular lipid accumulation through the induction of SREBP1c and its target genes. Given that protein kinase A (PKA) plays important roles in catabolic responses, activated PKA enhances the sumoylation of SREBP1c and potentiates the interaction between SREBP1c and PIASy. Notably, overexpression of PIASy in obese db/db mice ameliorated hepatic steatosis, while suppression of PIASy in lean (wild-type) mice stimulated hepatic lipogenesis with increased expression of SREBP1c target genes. Furthermore, PKA-mediated SREBP1c phosphorylation augmented SREBP1c sumoylation, subsequently leading to degradation of SREBP1c via ubiquitination. Together, these data suggest that PKA-induced SREBP1c sumoylation by PIASy is a key regulatory mechanism to turn off hepatic lipogenesis during nutritional deprivation.
Tissue adaptation to metabolic stress: insights from SUMOylation.
Xie H, Liu X, Li S, Wang M, Li Y, Chen T Front Endocrinol (Lausanne). 2024; 15:1434338.
PMID: 39588331 PMC: 11586182. DOI: 10.3389/fendo.2024.1434338.
Abnormal protein SUMOylation in liver disease: novel target for therapy.
Yang Y, Yu F J Mol Med (Berl). 2024; 102(6):719-731.
PMID: 38565749 DOI: 10.1007/s00109-024-02440-w.
Huang C, Yeh H, Lin R, Liao T, Shen H, Yang Y Am J Physiol Gastrointest Liver Physiol. 2024; 326(4):G385-G397.
PMID: 38252682 PMC: 11213477. DOI: 10.1152/ajpgi.00104.2023.
Fasting-sensitive SUMO-switch on Prox1 controls hepatic cholesterol metabolism.
Alfaro A, Dittner C, Becker J, Loft A, Mhamane A, Maida A EMBO Rep. 2023; 24(10):e55981.
PMID: 37560809 PMC: 10561358. DOI: 10.15252/embr.202255981.
The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications.
Gu Y, Fang Y, Wu X, Xu T, Hu T, Xu Y Exp Hematol Oncol. 2023; 12(1):58.
PMID: 37415251 PMC: 10324244. DOI: 10.1186/s40164-023-00420-3.